CMMB CMMB

Chemomab Therapeutics Share Price

4.10
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
4.10
Volume 2,707
Bid Price 4.01
Ask Price 4.10
News (1)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Chemomab Therapeutics Ltd CMMB NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 4.10 10:50:03
Open Price Low Price High Price Close Price Prev Close
4.14 3.88 4.1899 4.10
Trades Volume VWAP Dollar Volume Avg Volume
22 2,707  4.11  11,124 -
Last Trade Time Type Quantity Stock Price Currency
10:56:48 3  4.01 USD

Period:

Draw Mode:

Chemomab Therapeutics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 46.76M 11.40M 11.39M  -  - -1.18 -2.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - 857.27k -

more financials information »

News Chemomab Therapeutics

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

CMMB Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.


Your Recent History
NASDAQ
CMMB
Chemomab T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.